Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics reports half year 2019 results

  • Read more about Bone Therapeutics reports half year 2019 results

Bone Therapeutics to report half year 2019 results on 30 August 2019

  • Read more about Bone Therapeutics to report half year 2019 results on 30 August 2019

Bone Therapeutics: Information on the total number of voting rights and shares (July 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (July 2019)

Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

  • Read more about Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

Bone Therapeutics: Transparency notification received from Mr. J. Reymann

  • Read more about Bone Therapeutics: Transparency notification received from Mr. J. Reymann

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Bone Therapeutics successfully raises EUR 8.5 million

  • Read more about Bone Therapeutics successfully raises EUR 8.5 million

Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds

  • Read more about Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds

Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)

Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion

  • Read more about Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions